Dolby Laboratories (DLB)
(Delayed Data from NYSE)
$73.26 USD
+0.65 (0.90%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $73.33 +0.07 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Dolby Laboratories falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 957 | 818 | 1,272 | 1,127 | 925 |
Receivables | 262 | 244 | 233 | 180 | 189 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 36 | 24 | 11 | 26 | 32 |
Other Current Assets | 233 | 226 | 245 | 214 | 235 |
Total Current Assets | 1,488 | 1,311 | 1,761 | 1,547 | 1,382 |
Net Property & Equipment | 482 | 513 | 534 | 542 | 537 |
Investments & Advances | 98 | 103 | 63 | 52 | 180 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 202 | 184 | 156 | 119 | 114 |
Intangibles | 576 | 477 | 464 | 489 | 516 |
Deposits & Other Assets | 95 | 55 | 61 | 91 | 93 |
Total Assets | 2,980 | 2,690 | 3,106 | 2,917 | 2,822 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 21 | 14 | 18 | 13 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 351 | 230 | 263 | 220 | 268 |
Income Taxes Payable | 5 | 1 | 1 | 3 | 4 |
Other Current Liabilities | 32 | 19 | 18 | 15 | 20 |
Total Current Liabilities | 422 | 278 | 316 | 267 | 307 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 148 | 123 | 129 | 147 | 202 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 608 | 439 | 501 | 479 | 509 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 2,392 | 2,298 | 2,608 | 2,443 | 2,328 |
Other Equity | -20 | -47 | -4 | -5 | -15 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,372 | 2,251 | 2,604 | 2,438 | 2,313 |
Total Liabilities & Shareholder's Equity | 2,980 | 2,690 | 3,106 | 2,917 | 2,822 |
Total Common Equity | 2,372 | 2,251 | 2,604 | 2,438 | 2,313 |
Shares Outstanding | 95.20 | 95.90 | 101.10 | 100.30 | 100.10 |
Book Value Per Share | 24.92 | 23.47 | 25.76 | 24.31 | 23.11 |
Fiscal Year End for Dolby Laboratories falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 906 | 940 | 849 | 957 | 923 |
Receivables | 286 | 282 | 293 | 262 | 267 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 35 | 36 | 38 | 36 | 32 |
Other Current Assets | 242 | 294 | 271 | 233 | 247 |
Total Current Assets | 1,469 | 1,552 | 1,451 | 1,488 | 1,469 |
Net Property & Equipment | 478 | 481 | 479 | 482 | 502 |
Investments & Advances | 118 | 128 | 93 | 98 | 98 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 220 | 208 | 207 | 202 | 210 |
Intangibles | 553 | 561 | 570 | 576 | 604 |
Deposits & Other Assets | 97 | 71 | 97 | 95 | 86 |
Total Assets | 2,974 | 3,045 | 2,936 | 2,980 | 3,008 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 16 | 20 | 14 | 21 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 281 | 363 | 327 | 351 | 347 |
Income Taxes Payable | 12 | 8 | 6 | 5 | 11 |
Other Current Liabilities | 33 | 38 | 33 | 32 | 37 |
Total Current Liabilities | 355 | 443 | 394 | 422 | 423 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 136 | 145 | 148 | 166 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 526 | 607 | 573 | 608 | 625 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 2,463 | 2,450 | 2,367 | 2,392 | 2,397 |
Other Equity | -16 | -12 | -5 | -20 | -15 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,447 | 2,438 | 2,362 | 2,372 | 2,383 |
Total Liabilities & Shareholder's Equity | 2,974 | 3,045 | 2,936 | 2,980 | 3,008 |
Total Common Equity | 2,447 | 2,438 | 2,362 | 2,372 | 2,383 |
Shares Outstanding | 95.30 | 95.80 | 95.50 | 95.20 | 95.60 |
Book Value Per Share | 25.68 | 25.45 | 24.74 | 24.92 | 24.92 |